Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021

Emna Mziou,Aicha Hchaichi,Hejer Letaief,Sonia Dhaouadi,Mouna Safer,Khouloud Talmoudi,Rim Mhadhbi,Nawel Elmili,Leila Bouabid,Sondes Derouiche,Souha Bougatef,Hedia Bellali,Nissaf Bouafif ép Ben Alaya

DOI: https://doi.org/10.1016/j.vaccine.2024.02.028

IF: 4.169

2024-02-17

Vaccine

Abstract:Background In response to the COVID-19 pandemic, multiple vaccines to protect against COVID-19 disease have been developed rapidly. Precise estimates of vaccine effectiveness (VE) vary according to studies design, outcomes measured and circulating variants. The aim of this study was to evaluate the anti-covid-19 vaccine effectiveness in Tunisia. Methods We conducted a matched case-control study from 2nd to 15th August 2021. Cases and controls were subjects over 60 years of age, selected from the National testing database, regardless vaccine status. A standardized questionnaire was administered for cases and controls to collect information about vaccination status. For cases, vaccination status was defined based on the number of doses received before becoming ill and excludes doses received during the previous two weeks. For matched controls, a reference date based on the case's date of illness onset was defined in order to look at the control's vaccination status before its corresponding case became ill. The odds-ratio was calculated using simple conditional logistic regression. The VE (95 % confidence intervals) was calculated as (1 – odds ratio for vaccination) × 100 %. Results A sample of 977 matched peers for age and Gender, were included between August 2, and August 15, 2021. The overall vaccine effectiveness (VE) was 70 % [95 % CI 62.8–75.8 %]. Among our sample, 68.1 % of the male population and 56.4 % of the female population were vaccinated with a VE of 73 % [95 % CI 62.9–80.3 %] and 67 % [95 % CI 55.8–75.3 %] respectively, regardless vaccine scheme (complete or incomplete). VE was higher for the age group [60–70 years[ (72.3 % [95 % CI 62.8–79.3 %]). VE was 77.6 % [ 95 % CI 70.9–82.8 %] to prevent both symptomatic and asymptomatic forms of the disease. Moreover, in prevention from severe forms (treated with oxygen-therapy or admission to an Intensive-care-unit) VE was 86.6 % [ 95 % CI 75.6–92.7 %] and 98.4 % [ 95 % CI [79.2–99.8 %] in prevention from COVID-19 deaths with a complete anti-Covid vaccination scheme. Conclusion The results of our study showed that the anti-Covid-19 vaccines used in Tunisia are efficient to prevent both SARS-COV-2 infections and severe forms related to the disease. This study provided important data on the performance of vaccines in real-world settings that guide decisions about vaccine sustained use.

immunology,medicine, research & experimental